Azithromycin timing, duration does not affect hematologic relapse after pediatric HSCT

SALT LAKE CITY — Early azithromycin use did not affect hematologic relapse among pediatric hematopoietic stem cell transplant recipients, according to study results.
Duration of azithromycin use also had no effect on these outcomes, findings of an 8-year review presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
“Based on our findings, we think it is likely safe to use azithromycin in pediatric transplant recipients with hematologic malignancies outside of the engraftment period,” researcher Anthony Sabulski, MD, pediatric

SALT LAKE CITY — Early azithromycin use did not affect hematologic relapse among pediatric hematopoietic stem cell transplant recipients, according to study results.
Duration of azithromycin use also had no effect on these outcomes, findings of an 8-year review presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR showed.
“Based on our findings, we think it is likely safe to use azithromycin in pediatric transplant recipients with hematologic malignancies outside of the engraftment period,” researcher Anthony Sabulski, MD, pediatric